Sagimet's Denifanstat Shows Sustained Efficacy in 52-Week Acne Trial
Event summary
- Sagimet's license partner Ascletis presented 52-week Phase 3 OLE trial results for denifanstat in acne at EADV 2026, showing 57% IGA success rate and 72% reduction in total lesions.
- Denifanstat was well-tolerated with no adverse event-related discontinuations over 52 weeks.
- Sagimet plans to begin U.S. Phase 3 AURORA trial screening in October 2026.
- The trial enrolled 240 patients, with 116 receiving denifanstat and 124 switching from placebo.
The big picture
Sagimet's denifanstat represents a potential breakthrough in acne treatment, targeting a market of approximately 10 million people in the U.S. alone with moderate to severe acne. The sustained efficacy and safety data from the 52-week trial strengthen its position as a once-daily oral treatment with a novel mechanism of action. The upcoming U.S. Phase 3 trial will be critical in determining its commercial viability and regulatory approval prospects.
What we're watching
- Regulatory Pathway
- Whether the positive Phase 3 OLE results will accelerate denifanstat's regulatory approval process in the U.S. and other markets.
- Market Differentiation
- How denifanstat's novel mechanism of action will position it against existing acne treatments if approved.
- Commercialization Strategy
- The pace at which Sagimet can scale manufacturing and distribution to meet potential demand for denifanstat.